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Background: The Nasal Allergen Challenge (NAC) model allows the study of Allergic Rhinitis (AR) pathophysiology
and the proof of concept of novel therapies. The Allergic Rhinitis – Clinical Investigator Collaborative (AR-CIC) aims
to optimize the protocol, ensuring reliability and repeatability of symptoms to better evaluate the therapies under
investigation.
Methods: 20 AR participants were challenged, with 4-fold increments of their respective allergens every 15 minutes,
to determine the qualifying allergen concentration (QAC) at which the Total Nasal Symptom Score (TNSS) of ≥10/
12 OR a Peak Nasal Inspiratory Flow (PNIF) reduction of ≥50% from baseline was achieved. At the NAC visit, the
QAC was used in a single challenge and TNSS and PNIF were recorded at baseline, 15 minutes, 30 minutes,
1 hour, and hourly up to 12 hours. 10 additional ragweed allergic participants were qualified at TNSS of ≥8/12
AND ≥50% PNIF reduction; the Cumulative Allergen Challenge (CAC) of all incremental doses was used during
the NAC visit. 4 non-allergic participants were challenged with the highest allergen concentration.
Results: In the QAC study, a group qualified by only meeting PNIF criteria achieved lower TNSS than those achieving
either TNSS criteria or PNIIF+TNSS (p<0.01). During the NAC visit, participants in both studies reached their peak
symptoms at 15minutes followed by a gradual decline, significantly different from non-allergic participants. The
“PNIF only” group experienced significantly lower TNSS than the other groups during NAC visit. QAC and CAC
participants did not reach the same peak TNSS during NAC that was achieved at screening. QAC participants
qualifying based on TNSS or TNSS+PNIF managed to maintain PNIF scores.
Conclusions: Participants experienced reliable symptoms of AR in both studies, using both TNSS and PNIF reduction
as part of the qualifying criteria proved better for qualifying participants at screening. Phenotyping based on pattern of
symptoms experienced is possible and allows the study of AR pathophysiology and can be applied in evaluation of
efficacy of a novel medication. The AR-CIC aims to continue to improve the model and employ it in phase 2 and 3
clinical trials.
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Table 1 Total Nasal Symptom Scores (TNSS) Each symptom
(sneezing, congestion, itching, and rhinorrhea) is graded
from 0-3 by the participants during the screening and
NAC visits
Score Symptoms
0=None No symptoms evident
1=Mild Symptom present but easily tolerated
2=Moderate Definite awareness of symptom; bothersome but tolerable
3=Severe Symptom hard to tolerate; interferes with daily activity
The Nasal symptoms are then added for each time points to reach the TNSS.
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Allergic rhinitis (AR) is an upper airway inflammatory dis-
ease, characterized by symptoms of rhinorrhea, sneezing,
and nasal congestion. In addition, non-nasal symptoms
such as itching of the throat and/or palate, and conjunc-
tival symptoms can occur in individuals with AR with
exposure to their relevant allergen(s). Although AR is
often considered a benign condition, it greatly impacts the
quality of life of affected individuals, with economic costs
estimated at $5.3 billion per year in the USA [1,2]. World-
wide prevalence of AR is estimated at 9% to 42% [3,4],
however it is hard to quantify due to inconsistency of
population sampling methods that are employed in differ-
ent countries. There are also challenges when trying to
assess the efficacy of new medications in the treatment of
AR. Day-to-day variability in outdoor allergen concen-
tration, effects of weather including temperature and
humidity, as well as participant’s lifestyle, can all poten-
tially affect nasal and ocular symptom scores, common
outcomes in these studies [5,6].
A standardized and efficient model which controls
many environmental variables is essential to reliably
evaluate the efficacy of new medications in the treatment
of AR. One such model, the Environmental Exposure
Unit (EEU), is a model of human allergen exposure,
where allergen exposure is controlled, and patients can
be continuously monitored for symptoms [7,8]. EEUs are
effective and provide reproducible and reliable results,
but require special infrastructure and expertise that is
not commonly available at most sites [5]. The model,
however, does not allow for individual titration of the
allergen and biological sampling (e.g. nasal lavage) from
a large number of participants can be challenging.
Nasal Allergen Challenge (NAC) is another human
model of AR that involves the direct exposure of the
nasal mucosa to allergen. The NAC has the advantage of
running pilot studies with a small number of participants
as well as allowing biological sampling. The inflamma-
tory response that ensues, including early and late phase
reactions (in a subset of participants), is similar to that
observed in people with symptoms of AR during natural
exposure [9-11]. Disease pathophysiology and the effect
of medications can be studied through monitoring cyto-
kines and inflammatory cells, allowing for accurate mea-
surements of drug efficacy and onset/duration of action
for each group of participants experiencing early and/or
late phase responses as applicable to the mechanism of
action [12]. The NAC model has proven reliable through
many clinical trials of anti-histamines [13-16], intranasal
corticosteroids [17-20], and subcutaneous and sublin-
gual immunotherapies [21-24], albeit through variable
methodologies.
To address these issues, the Allergic Rhinitis – Clinical
Investigator Collaborative (AR-CIC) was formed withfunding from the AllerGen Network of Centres of
Excellence (AllerGenNCE). The AR-CIC is a Canadian
multi-center initiative with the primary goal of con-
ducting standardized NAC protocols to study the
pathophysiology of AR as well as the mechanism of
action and therapeutic effects of novel therapies. A re-
liable NAC model, would provide “a proof of principle”
that a novel medication may be effective, prior to pro-
ceeding to a clinical trial. The NAC model was chosen
as it is possible to test participants at multiple sites in
controlled conditions and outside of their respective
pollen season, where changes in symptoms or bio-
logical markers can be directly attributed to the NAC
and study medication [25,26]. The allergen dose ad-
ministered can be customized to the individual patient,
allowing all participants to achieve the required level
of AR symptoms.
Researchers have used a variety of methods to intro-
duce allergen into the nasal cavity, which have been
described elsewhere [6,25-34]. Several methods are avail-
able for measurement of the nasal symptoms experi-
enced by study participants. The Total Nasal Symptom
Score (TNSS) is the sum of scores for each of nasal con-
gestion, sneezing, nasal itching, and rhinorrhea at each
time point, using a four point scale (0–3), where 0 indi-
cates no symptoms, a score of 1 for mild symptoms that
are easily tolerated, 2 for awareness of symptoms which
are bothersome but tolerable and 3 is reserved for severe
symptoms that are hard to tolerate and interfere with
daily activity (Table 1). TNSS is calculated by adding the
score for each of the symptoms to a total out of 12.
Another method, the Visual Analogue Scale (VAS), is a
10 cm scale that ranges from “no symptoms” to “worst
symptoms ever” for each of the nasal symptoms [35].
Both methods are subjective, and thus depend on the
tolerance and perceptions of the participant, which may
cause variability in the data [36].
Peak Nasal Inspiratory Flow (PNIF) is another com-
monly used method for assessing nasal patency. PNIF
provides an objective measurement of nasal airflow ob-
struction. It has the advantage of being simple, non-
invasive and easily taught so participants can perform it
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nasal congestion and therefore can provide objective
confirmation of the subjective TNSS or VAS [26,37].
Repeating these measurements at intervals during the
study can help identify the onset of action of medications.
The aim of the AR-CIC was to develop and optimize
Standard Operating Procedures (SOPs) for each step of
the NAC model, including participant eligibility, aller-
gen introduction, symptom recording, and sample col-
lection, through the pilot studies described here. This
process allows multi-centre clinical trials to occur with
more consistency and reliability.Methods
This study was conducted following approval from the
Research Ethics Board of each site, and written in-
formed consent was obtained from each participant.Inclusion and exclusion criteria
Inclusion criteria included a history of developing AR
symptoms on exposure to an inhaled allergen to which
the participant had a positive skin prick test (≥3 mm
wheal compared to the negative control).
Participants were excluded if they had a history of a
clinically significant chronic disease deemed limiting to
tudy participation; a positive history for HIV, TB, HBV,
or HCV; any nasal structural abnormalities or polyps;
current signs/symptoms of active perennial rhinitis or
seasonal AR; a history of frequent nasal bleeding or
nasal surgery within the past 3 months; recent respira-
tory infection, or a history of smoking. Females who
were pregnant or planned on becoming pregnant were
excluded. A review of medical history and a nasal exam
were performed on each visit.
Asthmatic patients were excluded from this pilot study,
with the exception of exercise induced bronchospasm
requiring occasional use (≤2 times per week) of a short
acting beta agonist. A TNSS score of greater than 2 at
screening, immediately before the challenge, was reason
for exclusion since it indicated either AR from confound-
ing allergies or non-specific hypersensitivity. Participants
were instructed to refrain from taking allergy medica-
tions for the following periods of time before each
study visit; 30 day washout period for systemic cortico-
steroids and astemizole; 14 days for inhaled/intranasal/
intraophthalmic corticosteroids, cromolyn, leukotriene
receptor antagonists, and beta blockers; 7 days for H1
and H2 receptor blockers; 3 days for anti-allergic oph-
thalmic treatments; 48 hrs for decongestants; 24 hrs for
saline nasal sprays or ocular drops. Participants were
also excluded if they were receiving allergen specific
immunotherapy.Participants
Participants were recruited using multiple methods in-
cluding searching a database of potential study volun-
teers, advertising, or posters displayed in allergy clinics.
The Qualifying Allergen Concentration (QAC) study
was conducted at 4 sites across Canada and were as
follows from East to West: 5 participants at Université
Laval (Quebec City, PQ), 10 at Queen’s University
(Kingston, ON), 5 at McMaster University/St. Joseph’s
Healthcare (Hamilton, ON), and 3 at the University of
Alberta (Edmonton, AB). Two participants were excluded
because of missing data on some of the symptom diary
cards. An additional 4 people failed the screening process
during the QAC study.
At all 4 sites, a total of 20 healthy, ambulatory, male
and female participants between the ages of 18–65 years,
completed the QAC study involving a single concentra-
tion of allergen during the NAC visit. A follow-up study
using a Cumulative Allergen Concentration (CAC) was
conducted at Queen’s University with 10 allergic and 4
non-allergic participants, while 6 people failed the
screening process, due to not reaching the qualification
criteria following administration of the highest allergen
concentration.
Study design
Each study consisted of 2 visits, a screening visit with a
qualifying allergen challenge, and a NAC visit. The screen-
ing allergen challenge visit had to be conducted at least
7 days before the NAC visit. The allergen chosen for each
participant was determined using clinical history and skin
prick tests to a panel of common aeroallergens (ALK-
Abelló, Denmark and HollisterStier Allergy, USA). At
Queen’s University, all participants were challenged to
ragweed while other sites recruited participants allergic to
grass, house dust mite (D. pteronyssinus and D. farinae), cat
dander, or ragweed. Spirometry was used to measure FEV1
(Forced Expiratory Volume in the first second) to confirm
that it was safe for the participants to enrol in the study.
The qualifying participants were then challenged at
screening using titrated allergen concentrations to deter-
mine their qualifying allergen challenge dose. An initial
nasal wash with 5mls of 0.9% saline was used to identify
and exclude participants with non-specific nasal hyper-
responsiveness. Participants were asked to record their
baseline symptoms and PNIF scores (In-Check; Clement
Clarke International Ltd., Essex, UK). Individuals with a
TNSS greater than 2 were excluded.
Nasal allergen challenge
Allergen concentrations were prepared from stock solu-
tions (ALK-Abello at Queen’s and McMaster sites, Hollister
Stier at Laval and University of Alberta sites) in serial
dilutions from 1:2048 to 1:2: each concentration was a 4-
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dose (1:2048), 100 μL of the diluted allergen was sprayed
into each nostril using the Aptar Bi-dose device (Aptar
Pharma), and after 15 minutes PNIF and TNSS were re-
corded. If a PNIF reduction of ≥50% from baseline OR a
TNSS score of ≥10/12 were achieved, the qualifying
concentration to be used at the NAC visit was estab-
lished. If the target values were not reached, the con-
centration incrementally increased until either the
target PNIF or TNSS were achieved. If the participant
reached the highest concentration of 1:2 without quali-
fying they were excluded.
At the NAC visit the qualifying allergen concentra-
tion from the screening visit was used as the single
concentration for nasal challenge. PNIF and TNSS were
recorded by the participants before the challenge, then
at 15 min, 30 min, 1 hour, and then hourly for 12 hours
following the nasal challenge.
The CAC study conducted at Queen’s University used
a cumulative concentration of all the doses adminis-
tered during the screening visit and this new allergen
concentration was used at the NAC visit. For example,
a participant who qualified at 1:128 at screening would
receive a cumulative concentration of 1:98 (by adding
the individual allergen concentrations of 1:2048, 1:512,
and 1:128). The CAC also had a further modification in
the qualifying criteria, in that participants qualified when
they reached a PNIF fall of ≥50% AND a TNSS of ≥8/12.Symptom diary cards
Participants recorded their nasal symptoms on diary
cards that included symptoms of runny nose, nasal con-
gestion, sneezing and nasal itching. Each symptom was
scored from 0–3, 0 indicating the absence of the symp-
tom and 3 describing the symptom as severe and in-
tolerable [6,38,39] (Table 1). The card was designed for
automatic scanning and reading using Optical Mark
Recognition (OMR) to allow automated data entry into
the system.Statistical analysis
Graphpad Prism was used to generate the mean TNSS
or PNIF and standard error of the mean at each time
point of the NAC visits of the QAC and CAC studies.
One way repeated measures ANOVA with Tukey mul-
tiple comparisons was used to calculate the significance
of the mean at each time point by comparing all the
time points to baseline and to the peak TNSS time
point. The two-way repeated measures ANOVA with
Bonferroni multiple comparisons was employed in asses-
sing the different subsets of the QAC study. Correlation
between the mean TNSS with PNIF over time was stud-
ied using Pearson’s Coefficient while Student’s t-testhelped identify the statistical difference in TNSS at
screening and NAC visits for both studies.Results
Achieving the qualifying criteria in QAC study (screening
visit)
Based on the qualifying criteria for the QAC study, 13
participants met the PNIF criteria of 50% fall without
reaching a TNSS of 10/12, 4 participants met both cri-
teria, and 3 achieved a TNSS of 10/12 only. The group
that qualified based on “PNIF only” achieved a mean
PNIF fall of 64%, which is significantly different (p < 0.001)
from the “TNSS only” group who only scored a mean fall
in PNIF of 27%. A difference was also noticed when com-
paring TNSS results where the “PNIF only” group reached
a mean of 6.6 while the “TNSS only” group achieved a
mean of 10.6 (p < 0.01). The group that achieved both
qualifying criteria (PNIF fall of 50% AND a TNSS of 10/12
post NAC) was significantly different from the “TNSS
only” group when comparing PNIF fall (p < 0.01) and
different from the “PNIF only” group when comparing
TNSS (p < 0.01). The “TNSS + PNIF” group achieved simi-
lar PNIF falls as the “PNIF only” group and similar TNSS
scores to the “TNSS only” group, with no significant dif-
ference noted in these comparisons.Clinical responses at NAC during QAC study
The mean TNSS and PNIF are plotted for each time
point for all 3 groups of participants in the QAC study
during the NAC visit (Figure 1A-B). The 15 minute time
point is consistently the peak TNSS or the lowest PNIF
score for all 3 groups, after which there is a gradual drop
in TNSS or a rise in actual PNIF compared to baseline
measurements. The “TNSS only” group recorded the
lowest PNIF measurements at all time points while the
group that qualified using both criteria achieved similar
PNIF measurements to that experienced by the “PNIF
only” group (Figure 1B). There was no statistically sig-
nificant difference between the groups when comparing
PNIF scores. The “PNIF only” group experienced the
lowest TNSS with significant difference (p < 0.05) at
15 minutes compared to the “TNSS + PNIF” group, and
at 30 min. (p < 0.01), 1 hr (p < 0.001), and 2 hrs (p < 0.01)
compared to the “TNSS only” group (Figure 1A).
A further comparison of the highest TNSS score at
screening to the TNSS at 15 min. post NAC for each
group showed that there is a drop in the score although
only significant for “TNSS + PNIF” group (p = 0.0163)
(Figure 1C). The same analysis of PNIF fall show that
there is only a significant difference for the “PNIF only”
group (p = 0.0307) between the screening and NAC
visits, while the other groups maintained the same mea-
surements achieved in the screening visit (Figure 1D).








































































































































Figure 1 Analysis of QAC study. A - B show the mean and standard errors of TNSS and PNIF recorded by each group at each time point during
the NAC visit (significance between time points: p<0.0001). The “PNIF only” group experienced consistently low TNSS over all time points
(compared to “TNSS only” group: p<0.01 at 15 minutes and 1 hour, p<0.001 at 30 minutes; compared to “TNSS +PNIF” group: p<0.05 at 15
minutes) while the “TNSS only” group had the lowest PNIF recordings throughout the study. The “TNSS+PNIF” group had comparable TNSS
to the “TNSS only” group and comparable PNIF to the “PNIF only” group. C - D. All 3 groups experienced a decline in TNSS from screening
to NAC visit, but not all are statistically significant. “TNSS+PNIF” group had a significant (p<0.05) decline in NAC TNSS compared to screening. However,
“TNSS only” and “TNSS+PNIF” groups both had a non-significant increase in PNIF during the NAC from screening while the “PNIF only” group experienced
a decline (p<0.05).
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TNSS and PNIF scores for QAC participants were
grouped according to the type of allergen they were aller-
gic to (Table 2), whether seasonal or perennial, and then
compared their screening scores to the NAC scores. 14
participants were challenged with seasonal allergens
while 6 were challenged using perennial allergens. The
Queen’s University site only included ragweed allergic
(seasonal) participants while other sites chose allergen
using the participant’s largest skin test result. Partici-
pants challenged with perennial allergens were more
consistent in achieving the same TNSS scores during the
NAC compared to what they reached in screening. Par-
ticipants challenged with seasonal allergens experienced
lower TNSS during the NAC compared to screening
(p < 0.001). Making the same comparison using PNIF
fall showed that both participant groups with seasonaland perennial allergies experienced a decrease in PNIF
fall during the NAC but is not statistically significant.
Outline of QAC and CAC study results
The mean TNSS for all allergic participants at each time
point was plotted along with the standard error of the
mean (Figure 2A). Data from both studies followed the
same trend, with a peak in TNSS at 15 minutes post al-
lergen challenge followed by a gradual decline. Statistical
significance was achieved starting at 4 hours after aller-
gen exposure onwards compared to the peak during the
QAC study (15 min. vs 4 hrs, 5 hrs p < 0.05; 15 min. vs
6 hrs onwards p < 0.001) and starting from the 2 hour
time point for the CAC study (15 min. vs 2 hrs p < 0.05;
15 min. vs 3 hrs onwards p < 0.001). While allergic par-
ticipants in both studies had a significant change in
TNSS from baseline measurements (p < 0.0001), non-
Table 2 Allergen used for each participant and the concentration at which they qualified during the screening visit
QAC Study CAC Study
Study ID Allergen Max. Allergen Conc. Study ID Allergen Max. Allergen Conc.
Queen’s University
A046 109 Ragweed 1:128
Queen’s University
A083 117 Ragweed 1:8
A017 110 Ragweed 1:128 A015 114 Ragweed 1:128
A096 112 Ragweed 1:128 A053 118 Ragweed 1:32
A050 113 Ragweed 1:128 A044 119 Ragweed 1:32
A081 105 Ragweed 1:32 A079 116 Ragweed 1:8
A033 104 Ragweed 1:512 A056 115 Ragweed 1:2
A019 106 Ragweed 1:32 A016 125 Ragweed 1:32
A001 108 Ragweed 1:2048 A060 124 Ragweed 1:128
A066 103 Ragweed 1:128 A083 129 Ragweed 1:32
A090 102 Ragweed 1:512 A048 131 Ragweed 1:32
Université Laval
A070 301 Std D. farinae 1:32 A002 123 Non-Allergic 1:2
A095 302 Grass mix (5) 1:32 A061 126 Non-Allergic 1:2
A008 303 Grass mix (5) 1:32 A088 127 Non-Allergic 1:2
A038 304 D. pteronyssinus 1:32 A085 133 Non-Allergic 1:2
A073 305 Std D. farinae 1:512
McMaster University
AR001 D. pteronyssinus 1:32
AR002 Grass 1:2048
AR003 Cat hair 1:32
University of Alberta
A275 404 Grass mix 1:2
A749 405 D. farinae 1:32
Non-allergic participants in the CAC study did not meet the qualifying criteria even after challenge with the highest concentration (1:2). During the NAC visit, the
1:2 concentration was used once again.
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12 hours post exposure (p = 0.6044), suggesting the chal-
lenge did not cause nonspecific irritation (Figure 2A).
The mean PNIF at each time point also followed the
same pattern as the TNSS, showing the greatest PNIF
fall at 15 minutes post allergen challenge (QAC 15 min.
vs 3 hrs and onwards p < 0.001; CAC 15 min. vs 3 hrs
p < 0.05, 15 min. vs 5 hrs onwards p < 0.01) with a
gradual increase of air flow thereafter (Figure 2B). The
overall significance of the peak compared to baseline in
both studies is p < 0.0001. In comparison, non-allergic
participants did not experience any significant change in
nasal air flow (p = 0.1323).
Phenotypes of allergic rhinitis responses
For each of the studies, participants were separated into
one of 3 groups, Early Phase Responders (EPR), pro-
tracted Early Phase Responders (pEPR), and Dual Phase
Responders (DPR), depending on the TNSS pattern they
experienced over the 12 hour period (Figure 3A-B). EPR
had a decrease of ≥50% in TNSS by the 6th or 7th hour
and did not experience another increase in TNSS but ra-
ther a return to baseline by the 12th hour. DPR partici-
pants on the other hand had a sustained increase in
TNSS beyond the 6th or 7th hour time point. A thirdgroup of participants, pEPR, who did not experience a
50% decrease in TNSS and did not return to baseline by
the 12th hour.
Comparing protocols
Data collected from participants at Queen’s was used for
this comparison since this was the only site that con-
ducted both QAC and CAC studies, with 10 participants
in each. In doing so, only participants allergic to ragweed
were considered, eliminating any allergen-associated
variability in nasal response. Although the CAC study
achieved greater TNSS scores at screening, participants
in both studies did not reach their qualifying scores
when challenged at the NAC visit with the cumulative
dose.
Correlation between TNSS and PNIF
An inverse correlation exists between the subjective TNSS
and the objective PNIF; as the mean PNIF decreases the
mean TNSS increases (Pearson’s coefficient R2 = 0.8981
for QAC; R2 = 0.09576 for CAC) (Figure 2C,D).
Adverse events
No adverse events were reported.
























































































































CAC: Correlation TNSS vs PNIF














QAC: Correlation TNSS vs PNIF















Figure 2 Comparing QAC (Queen’s University only) and CAC studies. A and B. Mean TNSS and PNIF scores including non-allergic participants. Allergic
participants experienced the highest scores at 15 minutes (QAC TNSS: 15 minutes vs 4 and 5 hour time point p<0.05, vs 6th hour to 12th hour p<0.001)
(CAC TNSS: 15 minutes vs 2 hour p<0.05, vs 3 to 12th hour p<0.001) compared to non-allergic participants who did not experience change from
baseline. Most time points were significantly greater than baseline scores (QAC: Baseline TNSS vs 15 minutes to 3 hours p< 0.001 and p<0.01 at
the 4th and 5th hours) (CAC: Baseline TNSS vs 15 minutes to 2 hours p<0.001, vs 3rd hour p<0.01, vs 4th hour p<0.05). PNIF scores followed a
similar pattern (QAC PNIF: Baseline vs 15 and 30 minutes p<0.001, vs 1 hour p<0.01; while 15 minutes time point vs 3 hours to the 12th hour
p<0.001) (CAC PNIF: Baseline time point vs 15 minutes up to 1 hour p<0.001 and vs 2 hours p<0.05; while the 15 minute time point vs 3 hours
p<0.05, vs 5th to the 7th hour p<0.01, 8th hour p<0.001, 9th to the 11th hour p<0.01, and 12th hour p<0.001). While there were significant differences
between the time points for allergic participants (two way ANOVA p<0.0001 for both TNSS and PNIF in both studies), there were no such significance
experienced by non-allergic participants. C - D: Strong correlation between TNSS and PNIF exists in both studies, although the correlation is stronger
in the CAC study (Person’s correlation QAC: R2=0.8981 p<0.0001, CAC: R2=9576 p<0.0001).
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The pilot study helps fill a knowledge gap by evaluating
the most appropriate methodology for nasal allergen
challenge. We attempt to define what constitutes a posi-
tive response to allergen challenge, through modifying
the qualifying criteria, and investigating the effects of
allergen challenge given in a cumulative manner.
In this model, using simple inclusion criteria, such as
history of AR and positive SPT to allergen was sufficient.
From this pool, it is suggested that participants should
be excluded on the basis of having active AR, any nasal
structural abnormalities, and be able to observe washout
periods for anti-inflammatory medications as well as not
currently being treated with immunotherapy. From these
pilot studies we can conclude that the CAC study had a
better overall outcome for all participants by having a
more robust qualifying criteria, among other changes.Relying on either PNIF fall or TNSS alone as a meas-
ure of a positive challenge appears insufficient, since
participants that met criteria for one of the measures did
not necessarily meet the other. Both a minimum TNSS
and a PNIF fall are needed to increase the chances of re-
peating the same scores in the NAC visit. The “TNSS +
PNIF” group experienced significantly higher symptoms
than either groups that qualified on only one criterion,
similar to what was observed during screening.
Additionally, the “PNIF only” group did not manage to
maintain the PNIF reduction, while the other groups
did. The “TNSS + PNIF” group did not maintain their
TNSS score which might be due to a short fall of the
QAC protocol which uses a threshold dose allergen chal-
lenge protocol (as compared to the follow-up CAC
study). It might also be the result of the limited number





































































































Figure 3 Participants divided based on the phases of AR experienced based on TNSS. Participants in the QAC (Figure 3A) and CAC (Figure 3B)
studies who had an Early Phase Responders (EPR) and Dual Phase Responders (DPR) experienced a peak at 15 min. following NAC while those
that experienced a protracted EPR (pEPR) had a gradual rise in TNSS up to 1 hr. This suggests that the 1hr time point ensures that the maximal
amount of cytokines are secreted by this time point in all participants and therefore is the best time point for sampling nasal cytokines. While
EPR experienced a drop in TNSS following the peak, pEPR maintained their symptoms level before declining, DPR experienced a drop in TNSS
following the peak but did rise again later in the study. Statistical analysis was not possible since participant populations experiencing certain
phases were too small to compare. Nevertheless, differences in scores over the 12 hour period were distinct from one participant population to
the other.
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was needed and hence the CAC study was designed
where all participants qualified based on both a fall in
PNIF of 50% AND aTNSS of 8/12. The TNSS cut off was
decreased from 10/12 to 8/12, as 10/12 was considered
too challenging to achieve in general.
Participants in the QAC study qualified at lower con-
centrations than those in the CAC study (Table 2). This
is almost certainly due to the more flexible qualifying
criteria used in QAC (i.e. either a sufficient TNSS or
PNIF fall halted the screening challenge) which resulted
in participants qualifying earlier at a lower allergen con-
centration. In contrast, CAC participants qualified at
higher concentrations as they were required to meet
both the TNSS and PNIF criteria.
Participants challenged to a perennial allergen achieved
comparable change in TNSS in the NAC as they did in
the screening visit, unlike participants challenged with
seasonal allergens. Perennial allergens are in the partici-
pants’ environment on a continuous basis and so they
arrive to the study site “primed”, and more likely to
achieve their earlier TNSS. An influx of inflammatory
cells, such as eosinophils and basophils, during the late
phase of AR, is responsible for such an effect [3]. It is rec-
ommended to have a one week interval between screen-
ing and NAC visits to help avoid such a priming effect.
Ciprandi et al. studied the effects of nasal challenge per-
formed at different intervals, evaluating both symptom
scores and nasal cytology. The study concluded that a
one week interval produced findings similar to the base-
line challenge [40]. The use of non-standardized allergenextracts i is a potential limitation to our study, but to
minimize challenges with recruitment, we chose to allow
the use of non-standardized allergens if the skin test was
positive to that extract and it was the most clinically rele-
vant allergen for a given participant (e.g. ragweed or tree
pollen).
When comparing PNIF fall data, participants chal-
lenged with perennial allergens had greater variability
during the NAC, however, this was not significant.
Shortfalls of using PNIF alone were explained earlier.
Using the combined criteria of both TNSS and PNIF,
as subjective and objective measurements respectively, is
an adequate way to effectively measure the progress of
AR symptoms during direct NAC. Having a narrow
score range to select from (0–3), participants generally
do not avoid the extremes of the scale when assessing
their TNSS [38,41]. Participants found the scale easy to
use and did not require a significant amount of time to
choose an adequate value to represent their symptoms
and record it, especially during the short intervals be-
tween time points at the start of the NAC visit. Similarly,
participants did not have any difficulty following instruc-
tions for measuring PNIF on their own, which is particu-
larly important when considering recruiting large
number of participants for phase II/III clinical trials or
for studies requiring continued TNSS and PNIF record-
ing while at home.
TNSS and PNIF fall for both studies demonstrated a
strong correlation, indicating that using PNIF as an ob-
jective measurement is generally reliable in quantifying
the allergic reaction. PNIF has been previously validated
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Starling-Schwanz et al. who categorized participants based
on anterior nasal signs observed via anterior rhinoscopy
and correlated the results to PNIF [37]. Using PNIF and
TNSS measurements to evaluate AR is therefore consid-
ered an accurate and simple way to obtain data at such
frequent time points. Based on these measurements, the
two studies demonstrated the effectiveness of allergen
challenge via direct nasal spray as a valid method to chal-
lenge allergic participants.
The TNSS and PNIF pattern recorded during the
NAC visit of the CAC study were similar to the “TNSS
+ PNIF” group in the QAC study, consistently reaching
and maintaining higher TNSS and PNIF values. A sub-
set of participants in both studies observed a decrease
in TNSS and PNIF values during the NAC compared to
the screening visit. Thus the change to the qualifying
allergen dose ultimately administered appeared to ac-
complish more reliable results. Obtaining a robust re-
sponse to allergen challenge is important to not only
ensure one is including the most ‘allergic’ participants
in a study, but in the context of a clinical trial one would
have a greater symptom range to adequately assess the
medication under investigation.
TNSS and fall in PNIF peaked at 15 minutes post
NAC, which is consistent with previous studies of EPR
(Figure 3A-B) [26]. Participants who experienced a pEPR
in the QAC study reached their maximum symptoms
later at 30 min. to 1 hr post NAC, which might suggest
that the best time point to collect nasal samples for cyto-
kine analysis is at 1 hr post NAC (Figure 3A) [42]. 75% of
participants reached their peak TNSS by 15 minutes
post-NAC, and 85% reached their peak by 1 hour. All al-
lergic participants experienced the same consistent and
repeatable trend in TNSS and PNIF, according to their
respective group (EPR, pEPR, DPR), differing signifi-
cantly from the non-allergic participants.Conclusions
Participants experienced reliable symptoms of AR in
both studies and both dual responders and early phase
responders were noted, an observation that resembles
symptoms experienced by the general population [43,44].
This observation can be monitored in a study evaluating
the efficacy of a novel medication over the full length of
its duration of action [13,17,45]. Likewise, the NAC can
be used to study how symptoms and cytokines are
affected before and after immunotherapy as well as in
drug safety studies [23,24]. The model is a safe method of
studying medications in participants with asthma, since
the technique ensures the allergen remains in the nasal
cavity and is not inhaled into the lungs. Using the com-
bined criteria of TNSS and PNIF fall is a more robustmethod of determining a positive challenge to nasal aller-
gen administration.
Application of an optimized and standardized NAC
model with improved SOPs are planned at multiple collab-
orating sites, allowing the AR-CIC to study AR pathophysi-
ology and medication efficacy over a greater population
nationwide. This collaboration, part of the AllerGen
NCE, integrates the expertise of many researchers in fu-
ture studies.
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